Human immunodeficiency virus—induced immunosuppression: A risk factor for human papillomavirus infection

Matorras, Roberto; Ariceta, Jose M.; Rementería, A.; Corral, Jesús Perea; Terán, Gloria Gutierrez de; Díez, Javier de Miguel; Montoya, F.; Rodriguez-Escudero, F.J.

doi:10.1016/0002-9378(91)90620-7

Cited by 50 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HIV patients suffer from increased rates of HPV infection (a prevalence as high as 31-57% 6 ), with increased duration and persistence of disease. 6,7 It should be briefly noted that showing a direct correlation between HIV/AIDS-induced immunosuppression and acquiring HPV infection is difficult, given that HIV-infected persons may also be more likely to have sexual behavior, age characteristics, and other shared risk factors for HPV infection. 8 Patients with HIV commonly present with larger or more numerous warts that may not respond as well to treatment, have a higher HPV viral load within their warts, and have a higher prevalence of coinfection with HR HPV, particularly HPV-16.…”

Section: Immunocompromise and Humanmentioning

confidence: 99%

Human papillomavirus–related genital disease in the immunocompromised host

Gormley

Kovarik

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Human papillomavirus (HPV) is responsible for common condyloma acuminata and a number of premalignant and malignant anogenital lesions. These conditions are of particular concern in immunocompromised individuals who have higher risk of malignant transformation and are more difficult to treat. This is part I of a two-part review that will highlight the cutaneous features of condyloma acuminata and vaginal, vulvar, penile, and anal intraepithelial neoplasias, with an emphasis on presentation of these HPV-mediated diseases in the immunocompromised host. Counseling patients about these conditions requires a thorough understanding of the epidemiology, natural history of HPV, transmission and infectivity, risk of malignancy, and the role of the host immune response in clearing HPV lesions. Part II will provide an updated review of available treatments, with a focus on recent advances and the challenges faced in successfully treating HPV lesions in immunocompromised patients.

show abstract

Section: Immunocompromise and Humanmentioning

confidence: 99%

Human papillomavirus–related genital disease in the immunocompromised host

Gormley

Kovarik

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…[17][18][19][20][21][22] Immunodeficiency which follows HIV infection, was presented as an explanation for the unusually fast progression of cervical cancer in these patients, i) We report that HIV-cross-reactive 27 Gels were run at 100 V for [3][4] h. The molecular weights of proteins were estimated using high-range and lowrange prestained protein markers from Bio-Rad.…”

mentioning

confidence: 99%

Novel Family of Gynecologic Cancer Antigens Detected by Anti‐HIV Antibody

Rakowicz-Szulczynska

McIntosh

Morris

et al. 1994

Infectious Diseases in Obstetrics and Gynecology

View full text Add to dashboard Cite

Objective: The reactivity of gynecologic cancer proteins with monoclonal antibody (MAb) directed against the human immunodeficiency virus I (HIV-I) was tested.Methods: Cytoplasmic and nuclear proteins, extracted from a broad range of gynecologic cancers obtained during standard surgical procedures, were tested in Western blotting with MAb 5023 developed against the amino acid sequences 308-322 of the envelope protein gp120 of HIV-I.Results: Three cell membrane proteins, Mrl20,000 (p120), Mr41,000 (p41), and Mr24,000 (p24), and one chromatin protein, Mr24,000 (p24), were detected by MAb 5023 in invasive, poorly differentiated cervical squamous-cell carcinoma; ovarian serous cystadenocarcinoma; poorly and well-differentiated endometrial carcinoma; vulvar squamous-cell carcinoma; and malignant mixed mfillerian tumor. The same antigens were identified in cervical carcinoma cell line SiHa. Neither p120 nor p24 was recognized by other MAbs directed against the variable loop of gp120. Antigens p120 and p41 were undetectable in normal ovarian tissue and in biopsy samples ofnormal vaginal and rectal mucosa. Rectosigmoid cancer as well as colon carcinoma, lung carcinoma, and melanoma cell lines all tested negative.Conclusions: The identified antigens may represent either the products of human genes (proto-oncogenes) or, more likely, the products of an unknown virus specifically expressed in female cancer.

show abstract

“…Here, we introduce a new patient-applied ointment: AS101. AS101 is a low-molecularweight synthetic tellurium compound, which possesses immunomodulating, antiviral 19,20 and tumoricidal activities; 15,21-25 these properties have been shown to have beneficial effects in several preclinical and clinical studies. It has been suggested that AS101, as well as other tellurium-containing immunomodulators, stimulates the innate and acquired arm of the immune response.…”

Section: Discussionmentioning

confidence: 99%

“…18,19 Thus, the need to identify an effective agent that might support the natural immune response against this virus suggests AS101, a low-molecular-weight and low-toxicity immunomodulator, as a potential candidate.…”

mentioning

confidence: 99%